Loading...
•
Jun 30
•/
Sanofi Q2 2025 Earnings Report
Sanofi posted strong sales and earnings growth in Q2 2025, with standout performance in Dupixent and newly launched pharma products.
Key Takeaways
Sanofi delivered a solid Q2 2025 with 10.1% constant exchange rate sales growth and strong contributions from new product launches and immunology. Business EPS rose to €1.59, and net income more than tripled to €3.94 billion.
Revenue rose to €9.994 billion, up 10.1% at constant exchange rates.
Net income increased significantly to €3.94 billion from €1.11 billion the prior year.
Business EPS came in at €1.59 and IFRS EPS at €3.24.
Pharma launches grew 39.8% to €897 million, driven by ALTUVIIIO and Rezurock.
Sanofi
Sanofi
Sanofi Revenue by Segment
Sanofi Revenue by Geographic Location
Revenue by Segment
Immunology Revenue
CapyFin.comPharma Launches Revenue
CapyFin.comVaccines Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Sanofi raised its 2025 sales outlook to the upper end of high single-digit growth and confirmed a strong rebound in business EPS.
Positive Outlook
- Sales guidance raised to high single-digit growth.
- Business EPS expected to grow at a low double-digit rate at CER.
- Recent acquisitions like Blueprint and Vigil strengthen pipeline.
- Strong Dupixent performance including new COPD indication.
- Share buyback program nearly 80% completed.
Challenges Ahead
- Increased R&D spending compressed margins.
- Mixed results from itepekimab COPD Phase 3 studies.
- Operating income margin declined YoY.
- Some key franchises like Myozyme/Lumizyme saw sales drop.
- Currency headwinds impacted reported figures.
Revenue & Expenses
Visualization of income flow from segment revenue to net income